Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asheesh Sood

Gastroenterology Abingdon, MD Medical Doctor

NPI 1598727091 CMS profile 254421

100 Walter Ward Blvd Ste 100, Abingdon, MD 21009

Open in the dashboard

General payments

$6,357

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asheesh Sood of Abingdon, MD is reported in the CMS Open Payments database as having received $6,357 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,520 72
2024 General $1,385 62
2023 General $1,287 54
2022 General $662 26
2021 General $499 22
2020 General $179 12
2019 General $825 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asheesh Sood
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Asheesh Sood were reported at $1,520. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Asheesh Sood Gastroenterology median Middle half National median
2019 $825 $417 $126–$1,100 $163
2020 $179 $224 $74–$624 $114
2021 $499 $352 $106–$1,054 $132
2022 $662 $448 $129–$1,270 $149
2023 $1,287 $533 $150–$1,390 $160
2024 $1,385 $605 $160–$1,606 $164
2025 $1,520 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,650 88 payments
  2. E.R. Squibb & Sons, L.L.C. $763 6 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $724 50 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $549 22 payments
  5. Janssen Biotech, Inc. $386 20 payments
  6. Pfizer Inc. $312 17 payments
  7. Ironwood Pharmaceuticals, Inc $252 14 payments
  8. QOL Medical, LLC $167 7 payments
  9. Gilead Sciences, Inc. $163 9 payments
  10. Intercept Pharmaceuticals, Inc. $122 5 payments
  11. Other $1,268 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,357 284 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $724 50 payments
  2. CREON $602 31 payments
  3. LINZESS $540 28 payments
  4. ELIQUIS $390 3 payments
  5. CAMZYOS $373 3 payments
  6. VIBERZI $345 15 payments
  7. ENTYVIO $338 12 payments
  8. MAVYRET $310 17 payments
  9. STELARA $296 16 payments
  10. RINVOQ $294 16 payments
  11. Other $3,377 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,648

Median for Gastroenterology: 569

Drug cost

$425,819

Median for Gastroenterology: $104,976

Branded share of claims

29.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 28 $184,124
Creon Lipase/Protease/Amylase Brand 39 $97,238
Xifaxan Rifaximin Brand 19 $48,595
Linzess Linaclotide Brand 17 $23,701
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 232 $14,120
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 66 $11,266
Dexlansoprazole Dr Dexlansoprazole Brand 27 $9,986
Colestipol Hcl Generic 110 $8,112
Mesalamine Generic 31 $8,011
Pantoprazole Sodium Generic 557 $7,228

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$130,691

Medicare's payments for the services billed

Medicare patients

711

Average age 73

Services billed

1,172

377 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 35%
Ischemic heart disease 32%
Chronic kidney disease 24%
Depression 22%
Atrial fibrillation 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $291
$291 19 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $171
$171 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $105
  • AbbVie, Inc. $24
$129 17 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $127
$127 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record